A product review of vedolizumab in inflammatory bowel disease. Issue 10 (3rd October 2019)

• Record Type: Journal Article
• Authors: Battat, Robert; Dulai, Parambir S.; Jairath, Vipul; Vande Casteele, Niels
• Is Part Of: Human vaccines & immunotherapeutics. Volume 15:Issue 10(2019)
• Page Start: 2482
• Page End: 2490
• Publication Date: 2019-10-03
• Subjects: Anti-integrin therapy -- Crohn's disease -- gut-selective -- inflammatory bowel disease -- ulcerative colitis -- vedolizumab; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1591139
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients with inflammatory bowel disease (IBD). This product review outlines the unique mechanism of vedolizumab in addition to efficacy, safety, pharmacokinetic and pharmacodynamic data from clinical trials, observational studies and meta-analyses. Vedolizumab has been shown to be effective as a first- or second-line induction and maintenance therapy in both ulcerative colitis (UC) and Crohn's disease (CD). Prolonged induction therapy may increase efficacy, particularly in tumor necrosis factor-alpha-exposed CD patients. To date, no drug-specific safety signals have been identified. In addition to the presence of an apparent exposure-response relationship, vedolizumab has demonstrated consistent pharmacodynamic effects on α4β7, mucosal vascular addressin cell adhesion molecule 1 and other cell adhesion molecules. Future efforts should focus on identifying predictive biomarkers capable of guiding personalized IBD treatment with vedolizumab.